Pfizer reports positive results from phase III trial of Pregabalin
The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in
ACROBiosystems has upgraded its global licence solution for HEK293 functional cell lines, aimed at streamlining compliance to expedite biopharmaceutical research and development (R&D).
The company uses its Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body’s
The study, which recreated five earlier drug cardiac safety studies, utilized the proprietary Early Precision QT methodology developed by iCardiac Technologies. The results show highly significant improvement in